Score Overview
Explore the 2021 public Archive ranking →
Where Lakefront Biotherapeutics NV has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. LKFT does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 31.65 | — |
1 Year2025-10-23 | $ 32.03 | -1.19% |
5 Years2021-10-22 | $ 50.93 | -37.86% |
10 Years2016-10-21 | $ 65.74 | -51.86% |
All Time2015-05-14 | $ 50.50 | -37.33% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2015-05-14 |
|---|---|---|---|---|---|
| Price | $ 31.65 | $ 32.03 | $ 50.93 | $ 65.74 | $ 50.50 |
| Return | — | -1.19% | -37.86% | -51.86% | -37.33% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in EUR
| Year | |||
|---|---|---|---|
| TTM | € 990M | € 596M | € 2.23B |
| 2025 | € 1.11B | € 320M | € 2.99B |
| 2024 | € 275M | € 74M | |
| 2023 | € 239M | € 211M | |
| 2022 | € 241M | -€ 217M | |
| 2021 | € 234M | -€ 103M |

Lakefront Biotherapeutics NV fundamental performance
Between 2021 and 2025, revenue grew from € 234M to € 1.11B and net income went from -€ 103M to € 320M. Revenue increased in 60% of the years measured; net income in 60%.
Lakefront Biotherapeutics NV currently holds a 5-year HDB Score of 7.3 out of 10. How the HDB Score is calculated.
Membership
Explore LKFT with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Tactile Systems Technology IncTCMD· revenue grew in 100% of years
Amneal Pharmaceuticals, Inc. Class A Common StockAMRX· revenue grew in 100% of years
Incyte CorporationINCY· revenue grew in 100% of years
Oscar Health IncOSCR· revenue grew in 100% of years
Spero Therapeutics IncSPRO· revenue grew in 60% of years